Welfinac-MR Tablet is a combination medication containing Etoricoxib 60 mg and Thiocolchicoside 4 mg, formulated to provide effective relief from pain and inflammation associated with musculoskeletal conditions. Etoricoxib, a selective COX-2 inhibitor, exerts potent anti-inflammatory and analgesic effects by selectively blocking the cyclooxygenase-2 enzyme, thereby reducing the synthesis of pro-inflammatory prostaglandins. This mechanism helps alleviate pain and swelling in conditions such as osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and acute gouty arthritis. Thiocolchicoside, a muscle relaxant with anti-spasmodic properties, acts by modulating glycine receptors in the central nervous system, leading to the relaxation of skeletal muscles and reduction of muscle spasms. The synergistic action of these two components makes Welfinac-MR Tablet particularly beneficial in managing painful musculoskeletal disorders accompanied by muscle stiffness and spasms. It is indicated for short-term use in conditions such as lower back pain, muscle strains, and post-traumatic musculoskeletal injuries. Welfinac-MR should be used under medical supervision, considering contraindications such as hypersensitivity to its components, active gastrointestinal ulcers, and severe hepatic or renal impairment. Common side effects may include gastrointestinal discomfort, dizziness, and mild allergic reactions.